Ken Griffin Pro Qr Therapeutics N.V. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Pro Qr Therapeutics N.V. stock. As of the latest transaction made, Citadel Advisors LLC holds 1,800 shares of PRQR stock, worth $3,366. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,800
Previous 36,000
95.0%
Holding current value
$3,366
Previous $82,000
97.56%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding PRQR
# of Institutions
52Shares Held
17.2MCall Options Held
26.2KPut Options Held
8.6K-
Privium Fund Management B.V.5.58MShares$10.4 Million2.62% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.63MShares$6.78 Million0.01% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA2.04MShares$3.82 Million0.12% of portfolio
-
M28 Capital Management LP Stamford, CT1.02MShares$1.91 Million1.95% of portfolio
-
Dafna Capital Management LLC Los Angeles, CA906KShares$1.69 Million0.39% of portfolio
About ProQR Therapeutics N.V.
- Ticker PRQR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 71,362,096
- Market Cap $133M
- Description
- ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...